Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.56 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078485 | 1.00 | SYK (0.56) | SYKPSMB1CTSKADORA3ADORA2A | |
| SCHEMBL24073320 | 0.90 | SYK (0.54) | SYKPSMB1CTSKCTSLCTSB | |
| SCHEMBL25022027 | 0.90 | SYK (0.54) | SYKPSMB1CTSKCTSLCTSB | |
| SCHEMBL7965696 | 0.90 | PPARA (0.56) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL7297130 | 0.90 | PPARA (0.56) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL21293862 | 0.90 | CTSK (0.53) | SYKPSMB1CTSKADORA3ADORA2A | |
| SCHEMBL21293859 | 0.90 | CTSK (0.53) | SYKPSMB1CTSKADORA3ADORA2A | |
| SCHEMBL45447 | 0.90 | CASP1 (0.59) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL16689484 | 0.90 | CASP1 (0.59) | SYKCTSKCTSLCTSBCTSS | |
| SCHEMBL2619551 | 0.90 | CASP1 (0.59) | SYKCTSKCTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156780-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11951094-B2 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | AXIAL THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-4171547-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Axial Therapeutics, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| CN-115636903-A | Low-shrinkage resin and preparation method thereof | 浙江福雕文化创意有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-7081460-B2 | Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-07-25 | — | — | US | disclosed |
| EP-1389205-B1 | QUINAZOLINE AND QUINAZOLINE-LIKE COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | ORTHO MCNEIL PHARMACEUTICAL RE (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1389205-A1 | QUINAZOLINE AND QUINAZOLINE-LIKE COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | Ortho-McNeil Pharmaceutical Research Inc. (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030139398-A1 | Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-07-24 | — | — | US | disclosed |
| WO-2002081467-A1 | QUINAZOLINE AND QUINAZOLINE-LIKE COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | SYK 397/4885PSMB1 1791/4885CTSK 2969/4885 |
| US-20030139398-A1 | Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders | ITGB2, ITGB5, ITGB3 | SYK 1580/4885PSMB1 2459/4885CTSK 1661/4885 |
| US-20240156780-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | SYK 397/4885PSMB1 1791/4885CTSK 2969/4885 |
| US-11951094-B2 | TLR2 modulator compounds, pharmaceutical compositions and uses thereof | TLR2, TLR3, TLR4 | SYK 397/4885PSMB1 1791/4885CTSK 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.